Government
Senior White House adviser Andy Slavitt said the administration is striving to meet its goal of ensuring enough vaccine supply by summer, but acknowledged there could be some hurdles that will prevent that timeline.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 26, 2021.
Pfizer, Moderna, AstraZeneca, and Johnson & Johnson all have trials of their respective vaccines underway in various age-groups.
AstraZeneca spinout Albireo Pharma is moving closer to securing regulatory approval for its treatment known as odevixibat, for pruritus in patients with PFIC.
One year and more than 410,000 deaths later, the United States is still firmly in the grips of the COVID-19 pandemic.
The drug, a combination of cabotegravir and rilpivirine, is a complete therapy for HIV-1 infection in adults who are virologically suppressed.
The U.S. FDA has accepted Genentech’s supplemental New Drug Application and has granted Priority Review for the company’s unclassifiable interstitial lung disease (UILD) treatment Esbriet® (pirfenidone).
Hours after being sworn in as the 46th President of the United States, Joe Biden signed 10 executive orders that are aimed at combating the ongoing COVID-19 crisis.
Rochelle Walensky, who most recently served as chief of the division of infectious diseases at Massachusetts General Hospital, will become the new head of the U.S. Centers for Disease Control and Prevention under the administration of Joe Biden.
The U.S. FDA has granted rare pediatric disease and orphan drug designations for Taysha Gene Therapies’ AAV9-based gene treatment candidate currently in development for epilepsy caused by SLC13A5 deficiency.
PRESS RELEASES